Menactra

Menactra

vaccine, meningococcal

Manufacturer:

Sanofi Pasteur

Distributor:

Zuellig
Concise Prescribing Info
Contents
Meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine
Indications/Uses
Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y & W-135 in individuals 9 mth to 55 yr.
Dosage/Direction for Use
0.5 mL as a single IM dose preferably in the anterolateral thigh or deltoid region. Adult & childn 2-55 yr single dose. Childn 9-23 mth 2-dose series at least 3 mth apart.
Contraindications
Hypersensitivity. Guillain-Barre syndrome. Postpone vaccination in case of febrile or acute disease.
Special Precautions
Do not administer to patients w/ Guillain-Barre syndrome. Review the immunization history prior to administration. Risk of hemorrhage following IM inj. May diminish immune response in immunocompromised patients. Pregnancy & lactation. Infant <9 mth. Elderly >55 yr.
Adverse Reactions
Inj site pain & tenderness, irritability, diarrhea, drowsiness & anorexia; headache & fatigue.
Drug Interactions
May reduce the immune responses w/ immunosuppressants including irradiation, antimetabolites, alkylating agents, cytotoxic drugs & corticosteroids.
ATC Classification
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Presentation/Packing
Form
Menactra vaccine (inj)
Packing/Price
(vial) 0.5 mL x 1's;0.5 mL x 5 × 1's (P3,000/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in